Oncotarget

Research Papers:

A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations

Christina Demuth, Anne Winther-Larsen _, Anne Tranberg Madsen, Peter Meldgaard and Boe Sandahl Sorensen

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:31066-31076. https://doi.org/10.18632/oncotarget.25779

Metrics: PDF 579 views  |   HTML 1194 views  |   ?  


Abstract

Christina Demuth1,*, Anne Winther-Larsen1,*, Anne Tranberg Madsen1, Peter Meldgaard2 and Boe Sandahl Sorensen1

1Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark

2Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

*These authors have contributed equally to this work

Correspondence to:

Anne Winther-Larsen, email: Anne.Winther.Larsen@aarhus.rm.dk

Keywords: circulating tumour DNA; non-small cell lung cancer; next-generation sequencing; digital PCR; wild-type EGFR

Received: February 12, 2018     Accepted: June 12, 2018     Published: July 24, 2018

ABSTRACT

Background: The potentials of circulating tumour DNA (ctDNA) have been studied for non-invasive disease monitoring in patients with targetable mutations. However, the majority of cancer patients harbour no targetable mutations. A workflow including targeted next-generation sequencing (NGS) and droplet digital PCR (ddPCR) could be used for monitoring treatment in these patients. Thus, our aim was to evaluate the workflow for ctDNA monitoring in a cohort of non-small cell lung cancer patients.

Methods: Forty patients were prospectively included. Plasma samples were collected prior to and during treatment. NGS (Ion AmpliSeq Colon and Lung Cancer panel v2) was performed on ctDNA from pre-treatment samples. The identified mutations were monitored by ddPCR in consecutively collected samples.

Results: Mutations were detected in 21 patients. The most commonly mutated genes were TP53 (N=20) and KRAS (N=13). Treatment was discontinued due to non-response in 18 patients. In 16 of these, a simultaneous increase in ctDNA concentration was observed. A twofold ctDNA concentration increase confirmed in a second successive sample predicted non-response on the following imaging in 83% of patients (10/12).

Conclusion: ctDNA monitoring can be used for early detection of non-response in patients without targetable mutations, and therefore could supplement imaging data for treatment monitoring in this subset of patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25779